文献速递肝病

综述:MASH纤维化逆转——新兴疗法的前景

Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics.
PubMed 文献 · Aliment Pharmacol Ther · 2026-08-17

本文为叙述性综述,聚焦MASH抗纤维化治疗。resmetirom治疗52周纤维化改善至少1期达26% vs 安慰剂14%,semaglutide治疗72周达37% vs 22%。多种在研药物(FGF21类似物、双重/三重肠促胰素激动剂、泛PPAR激动剂)2期结果鼓舞,3期进行中。代偿性肝硬化需独立策略,组织学改善与非侵入指标改善同临床结局降低的关联尚未证实。

要点

  • resmetirom 52周纤维化改善≥1期26% vs 14%;semaglutide 72周37% vs 22%
  • 改善代谢功能障碍的药物抗纤维化表现优于靶向下游纤维化或炎症通路药物
  • 组织学或非侵入指标改善与临床结局降低的关联尚未证实

核心结论

  • 现有药物可实现MASH纤维化改善,新兴疗法前景可期。
  • 治疗诱导的组织学或非侵入指标改善与临床结局降低的关联仍未证实。

研究设计与样本

  • 叙述性综述,检索2期和3期试验、荟萃分析、流行病学数据及试验注册库。

主要发现

  • resmetirom治疗52周纤维化改善至少1期达26% vs 安慰剂14%。
  • semaglutide治疗72周纤维化改善至少1期达37% vs 安慰剂22%。
  • 靶向下游纤维化或炎症通路的药物在后期开发中成功有限,改善代谢功能障碍的药物表现更佳。
  • FGF21类似物、双重/三重肠促胰素激动剂、泛PPAR激动剂等2期结果鼓舞,3期进行中。

关键数值与推荐

  • resmetirom 52周纤维化改善≥1期26% vs 14%;semaglutide 72周37% vs 22%。

临床怎么用

  • resmetirom与semaglutide已获附条件批准用于MASH药物治疗。
  • 代偿性肝硬化需独立策略,平衡疗效与事件率并兼顾监管限制。

局限性

  • 治疗诱导的组织学或非侵入指标改善与临床结局降低的关联尚未证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is a leading indication for liver transplantation, and fibrosis stage most strongly predicts clinical outcomes. Pharmacologic treatment is now available with resmetirom and semaglutide holding conditional approval. AIMS: To describe the therapeutic landscape for MASH with a focus on anti-fibrotic impact. METHODS: Narrative review of Phase 2 and 3 trials, meta-analyses, epidemiological data, and trial registries. RESULTS: Historically, drugs targeting downstream fibrogenic or inflammatory pathways have had limited success in advanced development, whereas those improving metabolic dysfunction have had fared better. Fibrosis improvement by at least one stage was seen with resmetirom in up to 26% versus 14% placebo after 52 weeks and with semaglutide in 37% versus 22% after 72 weeks. Several agents in development (e.g., fibroblast growth factor 21 analogues, as well as dual and triple incretin agonists, pan-peroxisome proliferator-activated receptor agonist) report encouraging Phase 2 results, with Phase 3 trials ongoing. Compensated cirrhosis requires a distinct approach related to its fibrosis heterogeneity and burden of portal hypertension. This requires a delicate balance between efficacy and event rates that is further complicated by current regulatory constraints. CONCLUSIONS: Fibrosis improvement in MASH is attainable by available drugs with further promise from emerging therapies. The link between treatment induced histological improvement or improvement in noninvasive tests and reduction in clinical outcomes remains unproven. A rich therapeutic pipeline with the promise of combination regimens and increased focus non-invasive endpoints suggests that the future looks bright for patients living with fibrotic MASH.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ayoub M, Tsutsumi T, Rinella ME, et al. Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics. Aliment Pharmacol Ther. 2026. PMID: 42608656. doi:10.1111/apt.70921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。